Search results
FDA panel rejects MDMA-assisted therapies for PTSD despite high hopes from veterans
Fox News· 2 days agoA U.S. Food and Drug Administration (FDA) panel rejected MDMA-based treatments for post-traumatic...
Why FDA Panel Rejected MDMA Therapy—And What’s Next For Psychedelic Medicine
Forbes· 2 days agoHigh hopes that psychedelic medicines were finally on the pathway to regulation were dashed last...
MDMA’s Future As A Treatment For PTSD Is In Question
Inverse· 4 days agoWhile the FDA will still vote separately on MDMA, it generally follows the recommendation of its advisors, so its unlikely the novel treatment will gain approval... drug is ...
FDA rejects promising new therapy for PTSD, veteran advocates sound off: ‘Big gut punch’
BizPac Review· 2 days agoA Federal Drug Administration advisory panel has voted against authorizing MDMA-assisted therapy for PTSD. MDMA, more commonly known ...
Psychedelics Stocks Are Falling After a Shocking Vote at the FDA. Here's What You Need to Know.
Motley Fool via Yahoo Finance· 5 days agoDespite their votes, committee members signaled that they weren't opposed to an MDMA-based therapy...
After FDA setback, psychedelic drugmakers distance themselves from a pioneer
Washington Post via Yahoo News· 6 days agoCORRECTION: A previous version of this article misstated the position of Rick Doblin, founder of the...
Psilocybin Therapy Pilot Program Bill Introduced in California
High Times· 2 days agoA psilocybin treatment bill was recently introduced on June 6 by California Sen. Brian W. Jones and...
Should You Buy the Dip on Compass Pathways Stock?
Motley Fool via Yahoo Finance· 3 days agoUnlike most medicines intended for psychiatry, COMP360 has...for psychological support can squeeze the most efficacy out of the psychoactive component of...
NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter
KOLR - KSFX Ozarks· 5 days agoNRx Pharmaceuticals has now reached the 9-month stability point with its ketamine formulation (NRX-100) and has initiated 3 manufacturing lots for future drug release. The short-term need for ...